Senti Biosciences Net Worth
Senti Biosciences Net Worth Breakdown | SNTI |
Senti Biosciences Net Worth Analysis
Senti Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Senti Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Senti Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Senti Biosciences' net worth analysis. One common approach is to calculate Senti Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Senti Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Senti Biosciences' net worth. This approach calculates the present value of Senti Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Senti Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Senti Biosciences' net worth. This involves comparing Senti Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Senti Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Senti Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Senti Biosciences' net worth research are outlined below:
| Senti Biosciences had very high historical volatility over the last 90 days | |
| Senti Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 338 K. Net Loss for the year was (52.79 M) with loss before overhead, payroll, taxes, and interest of (29.78 M). | |
| Senti Biosciences currently holds about 140.78 M in cash with (41.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Will Senti Biosciences Turn Heads In 2025 - RTTNews |
Senti Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Senti Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Senti Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Senti Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Senti Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Senti Biosciences backward and forwards among themselves. Senti Biosciences' institutional investor refers to the entity that pools money to purchase Senti Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 120 | Ark Investment Management Llc | 2024-12-31 | 28.0 | Citigroup Inc | 2024-12-31 | 1.0 | Harbour Investments, Inc. | 2024-12-31 | 0.0 | Barclays Plc | 2024-12-31 | 0.0 | Nea Management Company, Llc | 2024-12-31 | 442.6 K | Vanguard Group Inc | 2024-12-31 | 97.5 K | Renaissance Technologies Corp | 2024-12-31 | 51.6 K | Geode Capital Management, Llc | 2024-12-31 | 27.5 K | Ubs Group Ag | 2024-12-31 | 19 K | Virtu Financial Llc | 2024-12-31 | 13.4 K |
Follow Senti Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.89 M.Market Cap |
|
Project Senti Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (0.72) | (0.76) | |
| Return On Assets | (0.54) | (0.57) | |
| Return On Equity | (2.06) | (1.96) |
When accessing Senti Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Senti Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Senti Biosciences' profitability and make more informed investment decisions.
Evaluate Senti Biosciences' management efficiency
Senti Biosciences has return on total asset (ROA) of (0.3302) % which means that it has lost $0.3302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Senti Biosciences' management efficiency ratios could be used to measure how well Senti Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.57. The current Return On Capital Employed is estimated to decrease to -0.76. As of now, Senti Biosciences' Non Currrent Assets Other are increasing as compared to previous years. The Senti Biosciences' current Total Current Assets is estimated to increase to about 63 M, while Other Assets are projected to decrease to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.04 | 11.60 | |
| Tangible Book Value Per Share | 11.04 | 11.60 | |
| Enterprise Value Over EBITDA | (0.02) | (0.02) | |
| Price Book Value Ratio | 0.63 | 0.60 | |
| Enterprise Value Multiple | (0.02) | (0.02) | |
| Price Fair Value | 0.63 | 0.60 | |
| Enterprise Value | 1.4 M | 1.3 M |
Understanding the operational decisions made by Senti Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 134.2161 | Revenue | Quarterly Revenue Growth (1.00) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Senti Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Senti Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Senti Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Senti Biosciences Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 17th of March 2025 Other Reports | ViewVerify | |
F4 | 14th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 13th of March 2025 Other Reports | ViewVerify |
Senti Biosciences Earnings per Share Projection vs Actual
Senti Biosciences Corporate Management
| Faraz Siddiqui | Senior Operations | Profile | |
| Thomas Chung | Vice Development | Profile | |
| Susan Kahlert | Controller | Profile | |
| Wilson Wong | Scientific Board | Profile | |
| Philip Lee | CoFounder CTO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.59) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.